Drug · Small Molecule

Linsitinib

CI-DRUG-00000345Explore in graph →NCIt C70982 CHEMBL1091644 CIViC Phase 3

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Phase 3	Trials	Jurisdictions	First approval	First trial
All cancers	Phase3	Phase 3	1	20	—	—	Jun 18, 2007
Malignant Breast Neoplasm	Phase2	Phase 2	0	1	—	—	2009-08
Malignant Liver Neoplasm	Phase2	Phase 2	0	1	—	—	Jan 10, 2011
Malignant Lung Neoplasm	Phase2	Phase 2	0	3	—

Curated evidence

Clinical evidence (8)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–8 of 8 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CDKN2A Loss1
Linsitinib + Palbociclib

Clinical trials

Trials with this intervention (20)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–20 of 20 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01186861	Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy	completed	Phase 2	205	Astellas Pharma IncINDUSTRY	9	Nov 18, 2025	clinicaltrials
NCT01221077	Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Molecule

Record

Kind: Small Molecule
Mechanism: Insulin-like growth factor I receptor inhibitor; Insulin receptor inhibitor
Targets: 2 genes
Aliases: ASP-7487, Cis-3-(8-Amino-1-(2-Phenylquinolin-7-yl)Imidazo(1,5-A)Pyrazin-3-yl)-1-Methylcyclobutanol, Cyclobutanol, 3-[8-amino-1-(2-phenyl-7-quinolinyl)imidazo[1,5-a]pyrazin-3-yl]-1-methyl, Cis-, IGF-1R Inhibitor OSI-906, Linsitinib, LINSITINIB (OSI-906), OSI-906, OSI906, OSI-906AA

Data updated 5 hours agoSource updated unknown

Identifiers

Codes (0)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

Data not yet available

No cross-reference code recorded yet beyond the record identifiers above.

Regulatory status is jurisdiction-specific and time-bound. Nothing on this page is a treatment recommendation.

CDKN2B Loss1
Linsitinib + PalbociclibSubstitutes	Ewing Sarcoma	Predictive	D	Supports Sensitivity Response	2	accepted	EID1880 A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohort… (full text at CIViC) PMID 27286459 · Murakami et al., 2016 · Open in CIViC	civic

CDKN2B Loss1

Linsitinib + PalbociclibSubstitutes

Ewing Sarcoma

Predictive

Supports Sensitivity Response

accepted

EID1880

A patient-derived xenograft (PDX) from a patient with cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) loss and FUS-ERG fusion positive Ewing's sarcoma was created. The PDX was treated in four cohort… (full text at CIViC)

PMID 27286459 · Murakami et al., 2016 · Open in CIViC

civic

IGF2 Overexpression3
Cabazitaxel + LinsitinibCombination	Malignant Prostate Neoplasm	Predictive	D	Supports Sensitivity Response	3	submitted	EID12428 OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… (full text at CIViC) PMID 25670080 · Vidal et al., 2015 · Open in CIViC	civic
Cabazitaxel + Docetaxel + LinsitinibSubstitutes	Malignant Prostate Neoplasm	Predictive	D	Supports Sensitivity Response	3	accepted	EID414 OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resi… (full text at CIViC) PMID 25670080 · Vidal et al., 2015 · Open in CIViC	civic
Linsitinib	Malignant Prostate Neoplasm	Predictive	D	Does Not Support Sensitivity Response	3	accepted	EID412 Increased IGF2 expression was shown to mediate chemotherapy resistance in several prostate cancer cell lines. The IGF1R/INSR inhibitor OSI-906 did not have a significant effect on chemotherapy resista… (full text at CIViC) PMID 25670080 · Vidal et al., 2015 · Open in CIViC	civic

IGF2 Overexpression3

Cabazitaxel + LinsitinibCombination

Malignant Prostate Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID12428

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resistant prostate… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

civic

Cabazitaxel + Docetaxel + LinsitinibSubstitutes

Malignant Prostate Neoplasm

Predictive

Supports Sensitivity Response

accepted

EID414

OSI-906, an IGF1R/INSR inhibitor, sensitizes cell lines to docetaxel and cabazitaxel, resulting in better overall survival in mouse xenografts of patient derived chemotherapy resistant castration-resi… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

civic

Linsitinib

Malignant Prostate Neoplasm

Predictive

Does Not Support Sensitivity Response

accepted

EID412

Increased IGF2 expression was shown to mediate chemotherapy resistance in several prostate cancer cell lines. The IGF1R/INSR inhibitor OSI-906 did not have a significant effect on chemotherapy resista… (full text at CIViC)

PMID 25670080 · Vidal et al., 2015 · Open in CIViC

civic

IGF1R Overexpression1
Crizotinib + Gefitinib + LinsitinibCombination	Salivary Gland Adenoid Cystic Carcinoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID9024 Within a preclinical study 15 patient samples with adenoid cystic carcinoma MYB-NFIB fusion activation loop can be modulated through AKT-dependent signaling induced by IGF1R overexpression and downreg… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC	civic

IGF1R Overexpression1

Crizotinib + Gefitinib + LinsitinibCombination

Salivary Gland Adenoid Cystic Carcinoma

Predictive

Supports Sensitivity Response

submitted

EID9024

Within a preclinical study 15 patient samples with adenoid cystic carcinoma MYB-NFIB fusion activation loop can be modulated through AKT-dependent signaling induced by IGF1R overexpression and downreg… (full text at CIViC)

PMID 28954282 · Andersson et al., 2017 · Open in CIViC

civic

NFIB Fusion2
Linsitinib	DOID:0080202UNRESOLVED	Predictive	D	Supports Sensitivity Response	2	submitted	EID12164 In a study of oncogenic signalling pathways, tumours and cultured cells from 15 patients with MYB-NFIB translocation-positive adenoid cystic carcinoma (ACC) were analyzed. Treatment with linsitinib, a… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC	civic
Crizotinib + Gefitinib + LinsitinibCombination	DOID:0080202UNRESOLVED	Predictive	B	Supports Sensitivity Response	2	submitted	EID12167 Treatment of ACC cells with a combination of linsitinib, crizotinib, and gefitinib resulted in synergistic inhibition of cell proliferation (p = 0.004). This combination also significantly downregulat… (full text at CIViC) PMID 28954282 · Andersson et al., 2017 · Open in CIViC	civic

NFIB Fusion2

Linsitinib

DOID:0080202UNRESOLVED

Predictive

Supports Sensitivity Response

submitted

EID12164

In a study of oncogenic signalling pathways, tumours and cultured cells from 15 patients with MYB-NFIB translocation-positive adenoid cystic carcinoma (ACC) were analyzed. Treatment with linsitinib, a… (full text at CIViC)

PMID 28954282 · Andersson et al., 2017 · Open in CIViC

civic

Crizotinib + Gefitinib + LinsitinibCombination

DOID:0080202UNRESOLVED

Predictive

Supports Sensitivity Response

submitted

EID12167

Treatment of ACC cells with a combination of linsitinib, crizotinib, and gefitinib resulted in synergistic inhibition of cell proliferation (p = 0.004). This combination also significantly downregulat… (full text at CIViC)

PMID 28954282 · Andersson et al., 2017 · Open in CIViC

civic